Advertisement

TRIAL SNAPSHOT

Acronym: EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

  • PHASE:
    2
  • NCT#:
    NCT00000000
  • STATUS:
    Not yet recruiting
  • START DATE:
    00/00/0000
  • LOCATION:
    United States, New York, NY
  • END DATE:
    00/00/0000
  • GENERIC DRUG NAME:
    Drug Name Here



Investigators

TRIAL ARTICLES

MORE TRIAL ARTICLES

Latest Conferences

VIEW ALL

Defining Benefit of Rucaparib Maintenance in Newly Diagnosed Ovarian Cancery

In publishing and graphic design, Lorem ipsum is a placeholder text commonly used to demonstrate the visual form.

Defining Benefit of Rucaparib Maintenance in Newly Diagnosed Ovarian Cancery

In publishing and graphic design, Lorem ipsum is a placeholder to demonstrate the visual form of a document or a typeface

Defining Benefit of Rucaparib Maintenance in Newly Diagnosed Ovarian Cancery

Lorem ipsum is a placeholder text commonly used to demonstrate the visual form of a document or a typeface